Gregg Fonarow MD

Substantial opportunity to improve HF care in US cardiology outpatient practices Findings from the @ACCinTouch NCDR PINNACLE registry jamanetwork.com/journals/jamac… @kofi_larry @SJGreene_md @JAMACardio

"I think what this tells us is that there are processes at the higher-use sites that can be emulated at the sites that are not at the same use rate for SGLT2s." @AbdelghaniRafei @gcfmd @SJGreene_md tctmd.com/news/key-subgr…

Let´s BE PROACTIVE, follow these 5 core principles for a rapid & intensive OMT in our HF pts: 1️⃣Avoid delay 2️⃣In-hospital initiation is essential 3️⃣Overcome risk-treatment paradox 4️⃣Acknowledge the safety profile 5️⃣Recognize risk of omission @SJGreene_md @gcfmd @JavedButler1

KARDIA-3: Zilebesiran as Add-on Therapy in Adults with Hypertension and Established Cardiovascular Disease or at High Cardiovascular Risk KARDIA‑3 aims to test whether a single 150–600 mg SC injection of zilebesiran, added to ≥2 background BP medications, can: •Achieve…

🚨 Finerenone Approved by US FDA in HF based on #FINEARTSHF Finerenone (Kerendia) is a non-steroidal MRA indicated to reduce the risk of CV death, hospitalization for HF, & urgent HF visits in adult patients with HF with LVEF>= 40% bayer.com/media/en-us/us…

Progress .... but still long way to go with implementing #SGLT2i for #HF in 🇺🇸 🚨 <1 in 6 w/ HF prescribed #SGLT2i 🚨 Adjusted for pt and practice characteristics, odds of SGLT2i varies by >4 fold depending on clinic pt goes to @JAMACardio @DCRINews jamanetwork.com/journals/jamac…

Sodium-Glucose Cotransporter 2 Inhibitor Use for Heart Failure in US Ambulatory Cardiovascular Care Although this study found that SGLT2i use had increased among ambulatory patients with HF during the study period, the majority of eligible patients did not receive this therapy.…

Five Studies We Are Looking For Ward in Heart Failure to at ESC 2025 Madrid DIGitoxin to Improve ouTcomes in patients with advanced chronic Heart Failure (DIGIT-HF): Baseline characteristics compared to recent randomized controlled heart failure trials Patients included in…

Five Studies We Are Looking For Ward in Heart Failure to at ESC 2025 Madrid Rationale and Design of the Dapagliflozin Effect on Cardiovascular Events in Acute Heart Failure (DAPA ACT HF)-TIMI 68 Trial Optimizing guideline-directed chronic HF therapies during HF hospitalization…

Study Highlights Rate of Sodium-Glucose Cotransporter 2 Inhibitor Use for Heart Failure hcplive.com/view/study-hig… via @hcplive @JAMACardio

Estimated Glomerular Filtration Rate Variability and Incident Heart Failure in Adults With Type 2 Diabetes Higher variability in eGFR is independently associated with an increased risk of incident HF in adults with type 2 diabetes sciencedirect.com/science/articl…

Prospective contemporary data suggest that higher ET-1 levels after HT are associated with accelerated CAV at 1 year @GCFMD @wfearonmd @KiranKhush1 @alinsairmd @DavidTehrani3 @jukakimMD @rushiparikh11 #AHAJournals ahajrnls.org/44Am9LG

Excited to see this work on ET-1 in CAV from my AHA Career Development Award published! Indebted to mentors @wfearonmd @KiranKhush1 @gcfmd and collaborators—truly a team effort. More to come!

In a nationwide study of outpatients with heart failure, a majority eligible for SGLT2i therapy did not receive it, particularly those who were older, female, or with higher blood pressure. ja.ma/4eLrYuA @GCFMD

Sodium-Glucose Cotransporter 2 Inhibitor Use for Heart Failure in US Ambulatory Cardiovascular Care Although this study found that SGLT2i use had increased among ambulatory patients with HF during the study period, the majority of eligible patients did not receive this therapy.…

The Failure of Life Expectancy to Fully Rebound to Prepandemic Levels in California jamanetwork.com/journals/jama/… @JAMA_current @boback

Industry marketing to general cardiologists led to 📈 uptake of ARNIs & SGLT2is, but not all pillars of #GDMT. Other mechanisms to increase MRAs & BBs, as well as ARNIs & SGLT2is, once generic options are available, are required. jacc.org/doi/10.1016/j.… #JACCHF #SGLT2i #HFrEF

In this pragmatic trial, an intervention that combined team-based primary care with automated identification of patients with antihypertensive medication nonadherence did not lead to improvements in adherence or blood pressure jamanetwork.com/journals/jamac… @JAMACardio